Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation.

Oncotarget - 23 Aug 2016

Saisana Marina, Griffin S Michael, May Felicity E B

Abstract excerpt

Amplification of seven oncogenes: HER2, EGFR, FGFR1, FGFR2, MET, KRAS and IGF1R has been identified in gastric cancer. The first five are targeted therapeutically in patients with HER2-positivity, FGFR2- or MET-amplification but the majority of patients are triple-negative and require alternative strategies. Our aim was to evaluate the importance of the IGF1R tyrosine kinase in triple-negative gastric cancer with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Extracellular Signal-Regulated MAP Kinases
Share to Gene Amplification

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins c-met

Share to ras Proteins

Share to Receptor, ErbB-2

Share to Receptor, Fibroblast Growth Factor, Type 2

Share to Receptor, IGF Type 1

Share to Receptors, Somatomedin

Source

Open in PubMed Open full text

Identifiers

PMID: 27437872
DOI: 10.18632/oncotarget.10642
PMCID: PMC5342354

Genes

FGFR2
KRAS
MET
BRAF
EGFR
FGFR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation.PMID 27437872Read ↗

Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapySemantic proximity Read ↗

Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancerSemantic proximity Read ↗

Insulin Receptor Isoforms and Insulin Growth Factor-like Receptors: Implications in Cell Signaling, Carcinogenesis, and ChemoresistanceSemantic proximity Read ↗

Drugging IGF-1R in cancer: New insights and emerging opportunitiesSemantic proximity Read ↗

Targeting the IGF1 axis in cancer proliferationSemantic proximity Read ↗

Role of insulin-like growth factor 1 receptor signalling in cancerSemantic proximity Read ↗

The IGF-I/IGF-I Receptor Pathway: Implications in the Pathophysiology of Thyroid CancerSemantic proximity Read ↗

The receptor for the type I insulin-like growth factor and its ligands regulate multiple cellular functions that impact on metastasis.Semantic proximity Read ↗

The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent InsightsSemantic proximity Read ↗

Insulin‐like growth factor ligands, receptors, and binding proteins in cancerSemantic proximity Read ↗

Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapySemantic proximity Read ↗

The Role of the IGF System in Cancer: From Basic to Clinical Studies and Clinical ApplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.